{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T16:27:35Z","timestamp":1749313655581,"version":"3.37.3"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients undergoing allogeneic haematopoietic stem cell transplantation (allo<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) are at risk of developing invasive fungal infections (<jats:styled-content style=\"fixed-case\">IFI<\/jats:styled-content>s). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) <jats:styled-content style=\"fixed-case\">IFI<\/jats:styled-content>\u2010associated morbidity and mortality rates and economic burden remain high. Despite their proven efficacy, it is currently unknown which is the most cost\u2010effective antifungal prophylaxis (<jats:styled-content style=\"fixed-case\">AFP<\/jats:styled-content>) agent. To determine the costs and outcomes associated with <jats:styled-content style=\"fixed-case\">AFP<\/jats:styled-content>, a decision\u2010analytic model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing allo<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> from the perspective of the Spanish National Health System. Generic itraconazole was the least costly <jats:styled-content style=\"fixed-case\">AFP<\/jats:styled-content> (\u20ac162) relative to fluconazole (\u20ac500), posaconazole oral suspension (\u20ac8628) or voriconazole (\u20ac6850). Compared with posaconazole, voriconazole was associated with the lowest number of breakthrough <jats:styled-content style=\"fixed-case\">IFI<\/jats:styled-content>s (36 vs 60); thus, the model predicted fewer deaths from breakthrough <jats:styled-content style=\"fixed-case\">IFI<\/jats:styled-content> for voriconazole (24) than posaconazole (33), and the lowest predicted costs associated with <jats:styled-content style=\"fixed-case\">other licensed antifungal treatment<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IFI<\/jats:styled-content> treatment in a cohort of 1000. Voriconazole resulted in cost savings of \u20ac4707 per patient compared with posaconazole. Itraconazole demonstrated a high probability of being cost\u2010effective. As primary <jats:styled-content style=\"fixed-case\">AFP<\/jats:styled-content> in allo<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> patients 180\u00a0days posttransplant, voriconazole was more likely to be cost\u2010effective than posaconazole regarding cost per additional <jats:styled-content style=\"fixed-case\">IFI<\/jats:styled-content> and additional death avoided.<\/jats:p>","DOI":"10.1111\/myc.12552","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T05:38:13Z","timestamp":1472189893000},"page":"79-88","source":"Crossref","is-referenced-by-count":4,"title":["Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant"],"prefix":"10.1111","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-0817","authenticated-orcid":false,"given":"Carlos","family":"Solano","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednico INCLIVA\u2010University of Valencia  Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Slavin","sequence":"additional","affiliation":[{"name":"Royal Melbourne Hospital  Melbourne VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa J.","family":"Shaul","sequence":"additional","affiliation":[{"name":"Evidera  Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol NHS Foundation Trust  Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[{"name":"H\u00f4pital Henri Mondor Assistance Publique\u2010Hopitaux de Paris and UPEC  Creteil France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Clinical Trials Centre Cologne Centre for Integrated Oncology K\u00f6ln Bonn Cologne Excellence Cluster on Cellular Stress Responses in Aging\u2010Associated Diseases German Centre for Infection Research University of Cologne  Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[{"name":"King's College Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lael","family":"Cragin","sequence":"additional","affiliation":[{"name":"Evidera  Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[{"name":"Hospital Universitari i Polit\u00e8cnic La Fe  Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Garcia\u2010Vidal","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Bellvitge L'Hospitalet de Llobregat  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Sorensen","sequence":"additional","affiliation":[{"name":"Evidera  Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Vanness","sequence":"additional","affiliation":[{"name":"University of Wisconsin and Visiting Scientist at Evidera  Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudie","family":"Charbonneau","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon Andoni","family":"Barrueta","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Peral","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"De Salas\u2010Cansado","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Bow","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba University of Manitoba  Winnipeg MB Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00805.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/11588370-000000000-00000"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt329"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12344"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12318"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1944-3"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080325"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2008.0015"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.175"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1545"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2008.01723.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12466"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0855-6"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08838.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2644"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268151"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-9-200305060-00006"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05900-11"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1288-9"},{"key":"e_1_2_10_23_1","unstructured":"Portalfarma.Bot PLUS 2.0 database.https:\/\/botplusweb.portalfarma.com. Last update2014. Date accessed August 2016."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1104-x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.272"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/522189"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2010.01286.x"},{"key":"e_1_2_10_28_1","article-title":"Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients\u2010A retrospective analysis of a single medical center in Taiwan","author":"Wang CH","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1130-6343(05)73629-1"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_2_10_32_1","unstructured":"HerbrechtR TissotF AgrawalS et\u00a0al.Update of the ECIL guidelines for antifungal therapy in leukemia and HSCT patients (ECIL 5).http:\/\/www.kobe.fr\/ecil\/telechargements2013\/ECIL5AntifungalTherapy.pdf. Last update2015. Date accessed August 2016."},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/11596540-000000000-00000"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767110-00004"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.4.3.457"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2010.01166.x"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-8-23"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9339-0"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.811078"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120599"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11665"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12552","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12552","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:08:27Z","timestamp":1696259307000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,26]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/myc.12552"],"URL":"https:\/\/doi.org\/10.1111\/myc.12552","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"type":"print","value":"0933-7407"},{"type":"electronic","value":"1439-0507"}],"subject":[],"published":{"date-parts":[[2016,8,26]]}}}